Natural Sciences Active Updated Nov 14, 2026
The orexin discovery reshaping narcolepsy treatment
Where it stands as of Nov 13, 2026
Stanford's Emmanuel Mignot is sharing the 2026 Albert Lasker Basic Medical Research Award for discovering in 1999 that orexin governs wakefulness. The discovery has now reached patients: oveporexton, the first orexin agonist, is prescribable in the US for adults with narcolepsy type 1. It is not yet known how far orexin-based treatment can extend to the much larger population of people with ordinary insomnia.
The story so far
-
Nov 14, 2026 Latest
STAT reported that Takeda's Orzeyful, the first narcolepsy treatment aimed at the underlying cause, is now available in the U.S. after the DEA cleared its last regulatory hurdle. The list price is $16,500 per 60-tablet bottle.
-
Nov 13, 2026
Psychiatric Times reported that oveporexton, the first drug that replaces the missing orexin signal behind narcolepsy type 1, is now available and prescribable in the US for adults.
-
Oct 10, 2026
ScienceAlert reported that people with narcolepsy have surprisingly youthful brains, and that scientists do not yet know why.
-
Sep 24, 2026
A study found orexin neurons act as an effort-tracking system in the brain, extending the chemical's known role beyond sleep and wakefulness, PsyPost reported.
-
Sep 12, 2026
Stanford's Emmanuel Mignot, who discovered in 1999 that the brain chemical orexin controls wakefulness by studying narcoleptic dogs including his own Chihuahua Watson, is sharing the 2026 Albert Lasker Basic Medical Research Award for the finding, which has since led directly to new narcolepsy and insomnia drugs.
This story moves with the morning letter.
When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.
Free for good. One click to leave.